24 HR mirabegron 8 MG/ML Extended Release Suspension [Myrbetriq] — RxCUI 2541237
RxNorm drug concept · Semantic branded drug
RxCUI 2541237
Semantic branded drug · SBD
● Current RxNorm concept 3 FDA products
7 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2541237
Official name24 HR mirabegron 8 MG/ML Extended Release Suspension [Myrbetriq]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as24 HR Myrbetriq 8 MG/ML Extended Release Suspension; Myrbetriq Granules 8 MG/mL 24HR Extended Release Suspension
FDA products mapped3
Package NDCs mapped7
Reported Medicaid activity (SDUD)186,535 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Mirabegron: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Mirabegron helps your bladder muscle relax so it can hold more urine before you feel a sudden urge to go. If you're dealing with overactive bladder — the urgency, the leaks, the co...
- What is mirabegron actually supposed to do for me?
- For adults taking the tablet, it doesn't matter — you can take it with or without food. But if a child is taking either the tablet or the oral suspension (granules), it should alwa...
- Does it matter if I take it with food or on an empty stomach?
🕸️ Concept Web — How 24 HR mirabegron 8 MG/ML Extended Release Suspen... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
24 HR mirabegron 8 MG/ML Extended Release Suspension [Myrbetriq]
RxCUI 2541237 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Mirabegron
1300786IN
-
Mirabegron
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Myrbetriq
1300792BN
-
Myrbetriq
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Mirabegron Extended Release Suspension
2541232SCDF -
Mirabegron Oral Liquid Product
2541231SCDG -
Mirabegron Oral Product
1300788SCDG -
Mirabegron Extended Release Suspension [Myrbetriq]
2541235SBDF -
Myrbetriq Oral Liquid Product
2541236SBDG -
Myrbetriq Oral Product
1300795SBDG -
Extended Release Suspension
316946DF -
Oral Liquid Product
1151137DFG - +1 more in this family
-
Mirabegron Extended Release Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
24 HR mirabegron 8 MG/ML Extended Release Suspension
2541233SCD -
Mirabegron 8 MG/ML
2541230SCDC -
Mirabegron 8 MG/ML [Myrbetriq]
2541234SBDC
-
24 HR mirabegron 8 MG/ML Extended Release Suspension
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
24 HR mirabegron 8 MG/ML Extended Release Suspension
SCD · 2541233 -
Mirabegron 8 MG/ML
SCDC · 2541230 -
Mirabegron Extended Release Suspension
SCDF · 2541232 -
Mirabegron Oral Liquid Product
SCDG · 2541231 -
Mirabegron Oral Product
SCDG · 1300788
Brand-Name Concepts
-
Mirabegron 8 MG/ML [Myrbetriq]
SBDC · 2541234 -
Mirabegron Extended Release Suspension [Myrbetriq]
SBDF · 2541235 -
Myrbetriq Oral Liquid Product
SBDG · 2541236 -
Myrbetriq Oral Product
SBDG · 1300795 -
Myrbetriq
BN · 1300792
📦 FDA Products & Package NDCs
3 products · 7 package NDCs
7 package NDCs map to RxCUI 2541237 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00469-2601-07 | 4 CARTON in 1 TRAY (0469-2601-07) / 1 BLISTER PACK in 1 CAR... | Myrbetriq | Astellas Pharma US, Inc. | 2012-06-28 |
| 00469-2601-30 | 1 BOTTLE in 1 CARTON (0469-2601-30) / 30 TABLET, FILM COATE... | Myrbetriq | Astellas Pharma US, Inc. | 2012-06-28 |
| 00469-2601-90 | 1 BOTTLE in 1 CARTON (0469-2601-90) / 90 TABLET, FILM COATE... | Myrbetriq | Astellas Pharma US, Inc. | 2012-06-28 |
| 00469-2602-07 | 4 CARTON in 1 TRAY (0469-2602-07) / 1 BLISTER PACK in 1 CAR... | Myrbetriq | Astellas Pharma US, Inc. | 2012-06-28 |
| 00469-2602-30 | 1 BOTTLE in 1 CARTON (0469-2602-30) / 30 TABLET, FILM COATE... | Myrbetriq | Astellas Pharma US, Inc. | 2012-06-28 |
| 00469-2602-90 | 1 BOTTLE in 1 CARTON (0469-2602-90) / 90 TABLET, FILM COATE... | Myrbetriq | Astellas Pharma US, Inc. | 2012-06-28 |
| 00469-5020-99 | 1 BOTTLE in 1 CARTON (0469-5020-99) / 100 mL in 1 BOTTLE | Myrbetriq | Astellas Pharma US, Inc. | 2021-03-25 |
Observed labelers:
Astellas Pharma US, Inc. (7)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.